A World of Discovery at Alnylam
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 6 programs in late-stage clinical development.
To view our corporate presentation, click here.
What’s in a Name?
Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Alnylam is derived from “Alnilam,” the center star in Orion’s belt, which shines the brightest of them all. It is also the Arabic word for “string of pearls.”